Starpharma commences phase 3 trial of VivaGel
Jackie Fairley, CEO, talks to BRR Media on the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.
Listen to the BRR Broadcast (external link)
Starpharma commences pivotal phase 3 VivaGel trials for bacterial vaginosis treatment
Melbourne Australia: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.
International licensing expert Peter Turvey joins Starpharma Board
Melbourne, Australia; Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the appointment of Mr Peter Turvey to the Board of Directors. Mr Turvey recently retired from CSL (ASX:CSL) as Executive Vice President Licensing for the R&D Division and Company Secretary after nearly two decades.
Mr Turvey brings to the Starpharma Board exceptional commercial licensing skills having worked at CSL since 1992 in various roles including Group General Counsel, Company Secretary and Executive Vice President Licensing.
Starpharma presenting at Citi investment conference in London
- CEO Dr Jackie Fairley presenting at the Citi Annual Australian and New Zealand Conference in London, 6th March 2012.
- Premier opportunity to further develop relationships with offshore investors.
- Starpharma selected as one of only four leading healthcare companies to present alongside 36 ASX listed companies.